DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Goto Y, Hotta N, Shigeta Y. et al.
Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Biomed Pharmacother 1995;
49: 269-277 doi:10.1016/0753-3322(96)82642-4
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.